Peptoran 150 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

peptoran 150 mg filmom obložene tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - ranitidinklorid - filmom obložena tableta - 150 mg - urbroj: 1 filmom obložena tableta sadrži 150 mg ranitidina u obliku ranitidinklorida

Peptoran MAX 150 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

peptoran max 150 mg filmom obložene tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - ranitidinklorid - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg ranitidina u obliku ranitidinklorida

Ranital S 150 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

ranital s 150 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb - ranitidinum - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg ranitidina u obliku ranitidinklorida

Gastrobel 150 mg šumeće tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

gastrobel 150 mg šumeće tablete

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica - ranitidinum - šumeća tableta - 150 mg - urbroj: jedna šumeća tableta sadrži 150 mg ranitidina u obliku ranitidinklorida

Peptoran 75 mg filmom obložene tablete ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

peptoran 75 mg filmom obložene tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - ranitidinklorid - filmom obložena tableta - 75 mg - urbroj: jedna filmom obložena tableta sadrži 75 mg ranitidina (u obliku ranitidinklorida)

Venclyxto ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.